Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.

Suppr

超能文献

作者信息

Ahmann D L, Bisel H F, Eagan R T, Edmonson J H, Hahn R G

出版信息

Cancer Chemother Rep. 1974 Nov-Dec;58(6):877-82.

PMID:4614896

Abstract

摘要

相似文献

Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.

Cancer Chemother Rep. 1974 Nov-Dec;58(6):877-82.

Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.

Cancer Treat Rep. 1978 Mar;62(3):449-50.

Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma.

Cancer Chemother Rep. 1974 Mar-Apr;58(2):251-3.

Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.

Cancer Chemother Rep. 1974 Nov-Dec;58(6):919-26.

A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.

Cancer. 1977 Aug;40(2):625-32. doi: 10.1002/1097-0142(197708)40:2<625::aid-cncr2820400206>3.0.co;2-m.

Combination chemotherapy for disseminated carcinoma of the breast.

Bol Asoc Med P R. 1975 Jun;67(6):157-63.

A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.

Cancer Res. 1974 Jan;34(1):27-30.

Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.

Cancer Treat Rep. 1977 Jan-Feb;61(1):47-50.

An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.

Surg Gynecol Obstet. 1974 Jan;138(1):77-80.

Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.

Cancer Chemother Rep. 1974 Nov-Dec;58(6):861-5.

引用本文的文献

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy.

Cureus. 2020 Feb 27;12(2):e7117. doi: 10.7759/cureus.7117.

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.

World J Clin Oncol. 2014 Aug 10;5(3):529-38. doi: 10.5306/wjco.v5.i3.529.

Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.

Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003368. doi: 10.1002/14651858.CD003368.pub3.

Single agent versus combination chemotherapy for metastatic breast cancer.

Cochrane Database Syst Rev. 2009 Apr 15;2009(2):CD003372. doi: 10.1002/14651858.CD003372.pub3.

Antitumour antibiotic containing regimens for metastatic breast cancer.

Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD003367. doi: 10.1002/14651858.CD003367.pub2.

Heat shock proteins and drug resistance.

Breast Cancer Res Treat. 1994;32(1):67-71. doi: 10.1007/BF00666207.

Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.

Cancer Chemother Pharmacol. 1982;7(2-3):231-3. doi: 10.1007/BF00254557.

Chemotherapy of breast cancer.

Med Oncol Tumor Pharmacother. 1984;1(3):169-92. doi: 10.1007/BF02934139.

Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.

Breast Cancer Res Treat. 1985;6(1):89-93. doi: 10.1007/BF01806014.

Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.

Invest New Drugs. 1985;3(2):139-48. doi: 10.1007/BF00174161.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验